About 300 reports

  • IMPORTANT INDICATIONS FOR ONCOLOGY BIOSIMILARS
  • Biologic Use Across Oncology

Colorectal Cancer: Competitive Landscape to 2026, April 2018, GDHC##CL GlobalData (2017).

  • Lymphoma
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • UPCOMING RELATED REPORTS
  • MARKETED DRUG PROFILE: ABBVIE AND JOHNSON & JOHNSON'S IMBRUVICA

UPCOMING RELATED REPORTS GLOBALDATA (2020) COLORECTAL CANCER: GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2028, TO BE PUBLISHED.

  • Drug Development
  • Lymphoma
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group
  • THIS REPORT IS AN UPDATE FROM HODGKIN LYMPHOMA: EPIDEMIOLOGY FORECAST TO 2024, OCTOBER 2015, GDHCER095-15.
  • 2 Hodgkin Lymphoma: Executive Summary

COLORECTAL CANCER: EPIDEMIOLOGY FORECAST TO 2028, NOVEMBER 2019, GDHCER##-## ##. ## RELATED REPORTS TABLE ## PRESENTS NEW DATA TYPES AND COUNTRIES ADDED TO THE REPORT.

  • Lymphoma
  • China
  • United Kingdom
  • United States
  • Forecast
  • ABBREVIATIONS

Clinical Targets Being Investigated for CAR Cell Therapies in Solid Tumors by Organ Group KEY TARGETS ARE EMERGING FOR CERTAIN CANCER TYPES, WITH IMPORTANT TARGETS IN OTHER CANCERS NOT SO WELL DEFINED EPCAM CD## Mesothelin Multiple PSMA FOLR## MET MUC## DLLR## PMEL Source: GlobalDat

  • Lymphoma
  • United States
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG
  • Phase of Development
  • VAGINAL CANCER

IN A STUDY THAT EVALUATED HER##/ NEU CAR-T CELLS IN PATIENTS WITH COLORECTAL CANCER, DEATH OF ONE PATIENT WAS REPORTED FIVE DAYS AFTER THE INFUSION OF T-CELLS.

  • Lymphoma
  • Company
  • Market Size
  • Juno Therapeutics Inc.
  • Novartis AG
  • Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer - Drug Profile
  • Rheumatoid Arthritis

The PRN## candidate, under Phase ## trial, is used in treating bladder cancer and solid tumors.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Novartis AG
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

The PRN## candidate, under Phase ## trial, is used in treating bladder cancer and solid tumors.

  • Immunotherapy
  • Lymphoma
  • Renal Cancer
  • Therapy
  • Novartis AG

AVASTIN IS MOST NOTABLY APPROVED FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER.

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

cancer fibrosis and thereby increase anticancer efficacy in a mouse model of colorectal cancer.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Product Initiative
  • Amgen Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

cancer fibrosis and thereby increase anticancer efficacy in a mouse model of colorectal cancer.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Product Initiative
  • Amgen Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019 (CONTD..1), H2 2019

cancer fibrosis and thereby increase anticancer efficacy in a mouse model of colorectal cancer.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Amgen Inc.
  • 3.1 THE U.S.

For example, HER## is a receptor is a overexpressed in several cancers (some breast or colorectal cancer subtypes).

  • Lymphoma
  • Medical Biotechnology
  • World
  • Forecast
  • Celgene Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

SMALL MOLECULES TO INHIBIT HDAC## FOR COLORECTAL CANCER - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Taipei Medical University NA NA Small Molecules to Inhibit HDAC## for Colorectal Cancer Small m

  • Cancer
  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Global Markets Direct Report Coverage

National Institutes of Health. treatment as the neoadjuvant therapy in advanced colorectal cancer.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Athenex, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020
  • PIPELINE BY ASCENTAGE PHARMA GROUP INTERNATIONAL, H1 2020

It is in preclinical stage of development for colorectal cancer, metastatic breast cancer and HER## positive gastric cancers.

  • Lymphoma
  • Therapy
  • United States
  • World
  • AbbVie Inc.

The American Cancer Society estimates ##, ## new cases of colorectal cancer will be diagnosed in the U. S. in 2017, and expects colorectal cancer to cause over ##, ## deaths in 2017.

  • Breast Cancer
  • Lymphoma
  • United States
  • Company Financials
  • Seattle Genetics, Inc.
  • Type of Therapy
  • Phase I/II

ADDITIONALLY, THE DRUG IS BEING EVALUATED FOR COLORECTAL CANCER IN PHASE II; HOWEVER, THERE ARE NO RECENT UPDATES ON ITS DEVELOPMENT.

  • Lymphoma
  • North America
  • United States
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019 (CONTD..1), H2 2019
  • PIPELINE BY PIQUR THERAPEUTICS AG, H2 2019

Its products are used for the treatment of breast cancer, colorectal cancer, renal cell carcinoma, prostate cancer, pancreatic cancer, multiple myeloma, hematological malignancies, and others.

  • Lymphoma
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • PIPELINE BY PIQUR THERAPEUTICS AG, H1 2020
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020 (CONTD..1), H1 2020

Its products are used for the treatment of breast cancer, colorectal cancer, renal cell carcinoma, prostate cancer, pancreatic cancer, multiple myeloma, hematological malignancies, and others.

  • Lymphoma
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020 (CONTD..1), H1 2020
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2020 (CONTD..1), H1 2020

This was a multicenter, randomized (##:##:##:##:##:##), double-blind, placebo-controlled study in adults with moderate to severe psoriasis.

  • Lymphoma
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018
  • DORMANT PRODUCTS, H1 2018 (CONTD..2), H1 2018

As of March 2012, it was in Phase II for metastatic colorectal cancer and as of January 2010, it was in Phase II for breast cancer (first line).

  • Lymphoma
  • Oncology
  • United States
  • World
  • Acetylon Pharmaceuticals, Inc.
  • PIPELINE BY ABBVIE INC, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

THE PHASE ## TRIAL IN COLORECTAL CANCER IS ONGOING, WITH A PRESENTATION OF THE RESULTS ANTICIPATED ON NOVEMBER ## AT THE 2005 EUROPEAN CANCER CONFERENCE (ECCO).

  • Hospital
  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • GlaxoSmithKline plc
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Dormant Products

SEP ##, 2015: HUYA BIOSCIENCE INTERNATIONAL ANNOUNCES EPIGENETIC BREAST CANCER PROGRAM HUYA Bioscience International announced expanding clinical trials with its lead cancer drug, HBI-##, starting with a Phase ## combination trial in support of a breast cancer pr

  • Cancer Hormonal Therapy
  • Lymphoma
  • China
  • Product Initiative
  • Chipscreen Biosciences Ltd
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019
  • Introduction

cancer fibrosis and thereby increase anticancer efficacy in a mouse model of colorectal cancer.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Amgen Inc.
  • PIPELINE BY GENENTECH INC, H2 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.
  • Epithelial Ovarian Cancer
  • PIPELINE BY AB SCIENCE SA, H2 2019

Those indications include the digestive cancers of GIST, gastric cancer and colorectal cancer, as well as prostate cancer.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020
  • selinexor

The drug candidate is in Phase I stage of development for myelodysplastic syndrome, gastrointestinal tumor, gastroesophageal (GE) junction carcinomas, prostate cancer and colorectal cancer.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.
  • Epithelial Ovarian Cancer
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2020

Those indications include the digestive cancers of GIST, gastric cancer and colorectal cancer, as well as prostate cancer.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Dormant Products
  • while the other trial is being run in China (NCT03538171) and is set to finish in 2020.

SEP ##, 2015: HUYA BIOSCIENCE INTERNATIONAL ANNOUNCES EPIGENETIC BREAST CANCER PROGRAM HUYA Bioscience International announced expanding clinical trials with its lead cancer drug, HBI-##, starting with a Phase ## combination trial in support of a breast cancer pr

  • Lymphoma
  • Therapy
  • China
  • Product Initiative
  • Chipscreen Biosciences Ltd
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019
  • Gastroesophageal (GE) Junction Carcinomas

The drug candidate is in Phase I stage of development for myelodysplastic syndrome, gastrointestinal tumor, gastroesophageal (GE) junction carcinomas, prostate cancer and colorectal cancer.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.